Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
Kyrollis AttallaRenzo G DiNatalePhillip M RappoldChristopher J FongFrancisco Sanchez-VegaAndrew W SilagyStanley WengJonathan ColemanChung-Han LeeMaria Isabel CarloJeremy C DurackStephen B SolomonVictor E ReuterPaul RussoTimothy A ChanRobert J MotzerNikolaus D SchultzEd ReznikMartin H VossA Ari HakimiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
RCC harbors a low prevalence of clinically actionable alterations compared with other tumors and the evidence supporting their clinical use is limited. These aberrations were found to be more common in advanced disease and seem to occur later during tumor evolution. Our study provides new insights on the role of targeted therapies for RCC and highlights the need for additional research to improve treatment selection using genomic profiling.